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Abstract
Combined bezafibrate (BEZ) and medroxyprogesterone acetate (MPA) exert unexpected antileukaemic activities against
acute myeloid leukaemia (AML) and these activities are associated with the generation of reactive oxygen species (ROS)
within the tumor cells. Although the generation of ROS by these drugs is supported by preceding studies including our
own, the interrelationship between the cellular effects of the drugs and ROS generation is not well understood. Here we
report the use of NMR metabolomic profiling to further study the effect of BEZ and MPA on three AML cell lines and to shed
light on the underlying mechanism of action. For this we focused on drug effects induced during the initial 24 hours of
treatment prior to the onset of overt cellular responses and examined these in the context of basal differences in metabolic
profiles between the cell lines. Despite their ultimately profound cellular effects, the early changes in metabolic profiles
engendered by these drugs were less pronounced than the constitutive metabolic differences between cell types.
Nonetheless, drug treatments engendered common metabolic changes, most markedly in the response to the combination
of BEZ and MPA. These responses included changes to TCA cycle intermediates consistent with recently identified chemical
actions of ROS. Notable amongst these was the conversion of a-ketoglutarate to succinate which was recapitulated by the
treatment of cell extracts with exogenous hydrogen peroxide. These findings indicate that the actions of combined BEZ and
MPA against AML cells are indeed mediated downstream of the generation of ROS rather than some hitherto unsuspected
mechanism. Moreover, our findings demonstrate that metabolite profiles represent highly sensitive markers for genomic
differences between cells and their responses to external stimuli. This opens new perspectives to use metabolic profiling as
a tool to study the rational redeployment of drugs in new disease settings.
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Introduction
Drug discovery is slow and prohibitively expensive resulting in low
rates of novel agents reaching the clinic [1–3]. The cost of developing
new drugs naturally deters the development of drugs in less common
diseases where profitability will be lower and excludes poorer nations
from benefiting from those drugs that do come to market. One
approach to alleviating this problem is to develop a better
understanding of old drugs that will permit their rational redeploy-
ment in new disease settings [1]. Metabolite concentrations represent
sensitive markers of genomic changes and responses of cells and
tissues to external stimuli [4–9]. Consequently, the development of
robust metabolomic platforms will greatly facilitate the understanding
of the in vitro and in vivo actions of available drugs and aid their
incorporation into novel therapeutic settings [10–13].
1H-NMR
spectroscopy permits highly reproducible chemical analyses that can
often becorrelatedto in vivo NMR spectra. Here we haveanalysed the
metabolic response profiles of acute myeloid leukemia (AML) cell
lines towardsdrugsnot conventionallyconsidered asleukemiaagents.
The AMLs are a genetically heterogeneous group of cancers
characterized by the abnormal maturation, survival and prolifer-
ation of myeloid cells in bone marrow [14]. The concurrent loss of
normal hemapoiesis results in life threatening insufficiency of
normal white and red blood cells, and platelets. Consequently if
untreated, patients suffer from anemia and increased risk of
infection and bleeding, and often die within weeks of diagnosis.
Although improved chemotherapy has benefited younger patients
the majority of patients still succumb to their disease [15]. What is
required are therapies that exert an antileukemic affect without
being myeloablative or systemically toxic.
We and others have previously shown the anti-leukemic actions
of the lipid lowering drug Bezafibrate (BEZ) and the contraceptive
steroid medroxyprogesterone acetate (MPA) against AML cells
[16,17] and have shown the more potent action of the drugs when
combined [18,19]. Treatment of AML cells with combined BEZ
and MPA resulted in growth cessation, and induction of
differentiation and apoptosis. The improved anti-leukemic actions
of combined BEZ and MPA appeared to converge on the
PLoS ONE | www.plosone.org 1 January 2009 | Volume 4 | Issue 1 | e4251accumulation of prostaglandin D2 (PGD2); BEZ increasing PGD2
synthesis and MPA inhibited its conversion to 11b-PGF2a by the
aldoketo reductase AKR1C3. Elevated PGD2 in turn gave rise to
elevation of the alternative downstream and potently anti-neoplastic
cyclopentanone prostaglandin 15deoxyD
12,14PGJ2 and the conse-
quent sustained generation of reactive oxygen species (ROS) [19].
However, the importance of ROS generation in mediating the
cellularresponsestocombined MPA and BEZorsomeotherhitherto
unrecognized effects ofthe drugs remained uncertain. Inthis study we
employed
1H-NMR metabolomics to functionally assign drug
induced changes in the metabolism of AML cell lines. We chose
cell lines that either apoptose in response to the drugs (KG1a and
K562) or that enter into differentiation (HL-60). This study identifies
unsuspected effects of MPA and BEZ on metabolites including those
of the TCA cycle that support the importance of ROS in mediating
the drugs’ effects and also highlights differences associated with either
differentiation or apoptotic responses. Moreover, our study demon-
strates the applicability of
1H-NMR metabolomics as an analytical
tool for the understanding of drug-drug interactions.
Results
1H-NMR profiles reveal distinct differences between AML
cell lines
We first recorded
1H-NMR spectra of exponentially growing
HL-60, KG1a and K562 cells. These cell lines represent highly
undifferentiated AMLs (KG1a), more differentiated AMLs (HL-
60) and AML blast crisis arising from a predisposing chronic
myeloid leukaemia (CML; K562). Figure 1a shows the morphol-
ogy of exponentially growing cells from these cell lines and shows
that the basal rates of apoptosis and differentiation in these cell
lines are low. Projected J-resolved NMR spectra (J-RES) revealed
significant differences between the cell lines (Figure 1b) that were
stable and highly reproducible. An expanded section (1.95–
2.2 ppm) of the
1H-NMR spectra of the 12 replicates of each cell
line for KG1a, K562 and HL-60 highlights the excellent
reproducibility of the independently grown cell samples.
Multivariate statistical modeling using principal component
analysis (PCA) was performed on the
1H-NMR spectra of 12
independently grown replicates from each of the cell lines and the
scores plot (principal components 1 vs 2) resulting from PCA
(Figure 1c) revealed very clear discrimination between the intracel-
lular metabolome of the three cell lines. It must be emphasized that
these differences were identified using an unsupervised analysis, i.e.
without any prior information about the samples. Since all three cell
lines were grown under identical conditions the observed discrimi-
nation demonstrates that the genetic differences between the cell lines
are strongly represented by their individual metabolic profiles.
Loadings plots for the first principal component of the pairwise
comparison between the three cell lines identified lactate, alanine,
N-acetyl-aspartate, creatine, phosphocholine and myo-inositol as
major discriminators between the cell lines (Figure S1). Lactate
and N-acetyl-aspartate were both elevated in HL-60; alanine was
high and creatine low in HL-60 and KG1a; phosphocholine was
lower in K562 and myo-inositol had lower levels in HL-60. The
ability to distinguish cell lines so accurately represents significant
progress for metabolic phenotyping of cancer cells and forms a
basis for profiling differing tumor backgrounds as well as shared
and non shared drug responses.
1H-NMR profiles depict the response of AML cell lines to
bezafibrate and medroxyprogesterone acetate
Our previous studies identified antileukaemic actions of combined
MPA and BEZ (MPA+BEZ) against AML cells and cell lines that
result in either cessation of cell proliferation accompanied by
differentiation or by entering into apoptosis [19]. In this study we
wished to investigate whether a metabolomic approach could
identify signatures associated with these events and whether these
signatures provide new insight into the mechanistic actions of this
new experimental approach. HL-60 cells were chosen as a line that
responds to MPA+BEZ by entering into differentiation and KG1a
and K562 as cell lines whose primary response is apoptosis. We
wished to identify signatures indicative of drug responses at times
prior to any marked cellular changes. Figure 2a shows that very little
differentiation of HL-60 cells or apoptosis of either KG1a or K562
cells wereobserved after24 hours exposureto MPA+BEZ.However
these processes were subsequently evident at 96 hrs. We therefore
performed our metabolomic analyses at 24 hours post treatment.
The PCA scores plot shown in Figure 2b demonstrates that
exposure of the cells to the drugs alone or in combination caused
changes in the metabolome of all three cell lines. It is notable that
despite the ultimately profound anti-leukemic effects of the drugs
the changes induced at 24 hours were less marked than the pre-
existing differences determined by the genetic backgrounds of the
cell lines. Alterations provoked by the drugs were greatest in HL-
60 cells but remained small when compared to the inherent
differences between cell types. Importantly, even in the presence of
drugs, reproducibility between replicates (12 per treatment for
each treatment and cell line) remained very high and sample to
sample variation within each group was significantly smaller than
any variation arising from treatment or genetic variability. The
relatively subtle but distinct metabolic changes seen in response to
drug treatments allied with the lack of overt cellular changes at
24 hours, strongly imply that we have measured genuine drug
responses and not secondary changes within the metabolome
occurring after drug induced changes in cell behavior.
1H-NMR profiles reveal combinatorial effects of MPA+BEZ
treatment
The specific metabolic changes induced by the different drug
treatments were further investigated by performing PCA on the
1H-NMR datasets of each cell line. The scores plots (PC1 vs PC2)
obtained from these analyses (Figure 3) depict excellent grouping
and separation for the different treatments in each of the three cell
lines. It is noteworthy that, for all the cell lines, the treatments with
and without BEZ are always separated along the first principal
component.
For KG1a, the separation between different treatments along
PC2 is well resolved and separates treatments with and without
MPA (regardless of BEZ); however, the treatments containing
MPA, and with or without BEZ, are on opposite sides of the PC2-
axis null point. Separation in PC2 is good for K562 although not
as clear as for KG1a. Furthermore, separation between BEZ
treatment alone and combined MPA+BEZ treatment in HL-60 is
incomplete, indicating less pronounced additional changes in-
duced by combining the two drugs.
The excellent grouping and separation obtained from the
aforementioned analysis encouraged us to further study the effects
of the drug treatments on metabolic changes in the different cell
lines and, eventually to try to identify the mechanism by which
these drugs, and in particular the combination treatment, exert
their function. To achieve this, each of the drug treatments were
separately compared to the solvent control datasets (within each
cell line) using PCA (scores plots obtained for KG1a cells are
included in Figure S2(a–c)). In all cases this analysis led to a clear
separation of the two treatments along PC1. These loadings were
therefore used to identify discriminatory compounds for functional
annotations (Figure 4).
Drug Responses in AML Cells
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indicated that a subset of metabolites was modulated in similar
ways in all cell lines. Importantly, this was most marked when the
combination treatment was compared to the controls suggesting
that a common mechanism may underlie those changes. The
concordant changes observed in response to combined treatment
centered on metabolites intimately associated with the TCA cycle,
some amino acids and other metabolites. For example, the amino
acids valine, leucine and isoleucine were all present in higher
concentrations in combination treatment samples as were
glutamine, glutamate, glycine, succinate, and acetate. However,
differential effects were also observed between non-differentiating
KG1a and K562 cells when compared to HL-60 cells. For
example fumarate accumulated in MPA+BEZ treated KG1a and
K562 cells but was depleted in HL-60 cells. Perhaps in association
with this aspartate accumulated in HL-60 cells but was depleted in
KG1a and K562 cells. In addition, the response observed for
glutamate is different for KG1a and K562 where MPA showed
reduced levels and BEZ and combined treatment showed both
increased levels whereas the effect of MPA was more dominant in
HL-60 causing increased levels (in MPA and combined treatment)
whereas BEZ alone caused lowered levels of glutamate.
Addition of reactive oxygen to extract of non drug-
treated cells results in drug like effects
Oxidative stress has been associated with TCA cycle dysfunc-
tion [22,23]. In addition, previous reports have established that
ROS mediate the non-enzymatic conversions including that of a-
ketoglutarate into succinate [24–26]. As shown in Figure 5 and
Figure S3, depletion of a-ketoglutarate and accumulation of
succinate was a common drug response across all three cell lines.
We therefore considered whether the perturbations of TCA
intermediates seen in response to BEZ and MPA may relate to our
previous observations of the ability of the drugs to generate ROS
in AML cells [19]. To test this we monitored the in vitro effect of
different concentrations (0.2, 0.8 and 2 mM) of hydrogen peroxide
(H2O2) on KG1a cell extracts taken from non-drug treated cells.
An expanded section of the acquired NMR spectra upon addition
of H2O2 is shown in Figure 6 (for clarity the NMR spectrum
obtained upon addition of 2 mM has been omitted because its
profile was superimposed to 0.8 mM H2O2 NMR spectrum).
Despite the apparent severity of this treatment the profile of the
majority of metabolites remained unchanged. However, notable
and highly selective changes where observed. As consistent with
oxidative stress we observed depletion of reduced glutathione
(GSH) and concurrent accumulation of oxidized glutathione
(GSSG). Moreover, and consistent with the response to combined
BEZ and MPA, H2O2 treatment was also associated with a clear
reduction in a-ketoglutarate with concurrent gain of succinate.
In contrast, acetate and malonate don’t accumulate in H2O2-
treated extracts form KG1a cells owing to the transiently low
concentration of pyruvate and oxaloacetate in cell extracts.
However, in vitro treatment of oxaloacetate and pyruvate confirm
that these conversions are in fact induced by hydrogen peroxide as
shown in Figure S4.
Discussion
Relevance of metabolic profiling of cancer cells
Cancer cell lines are well established models to study specific
cellular mechanisms characteristic for different types of cancer,
usually by monitoring specific proteins and their actions. Recent
advances in ‘omics’ technologies allow for more systematic
investigations to characterize parameters like gene expression,
protein and metabolite profiles [4,20]. The advantage of ‘omics’
technologies lies in their multiparametric nature probing a large
array of indicators at the same time. For the application of ‘omics’
technologies to the understanding of drug action, it is essential that
effects of drugs produce a sensitive response which can be
reproduced with sufficiently high quality. Here we have shown
that metabolic profiling of cancer cells can not only identify
phenotypic differences between cell lines but can also sensitively
detect and distinguish changes in metabolite concentrations
induced by relatively short exposure to differing drugs. It is
important to mention that all treatments caused a distinct
reproducible profile which is observed in unsupervised PCA.
The schematics shown in Figure 5 and Figure S3 depict the
commonalities and differences in changes in metabolites when
each of the cell lines was treated with combined MPA+BEZ.
These figures powerfully illustrate that a common metabolic
response underlies the perception of the drugs in independent
AML cell lines with markedly differing constitutive metabolomes.
For the functional relevance it is essential that two similar cell
lines, K562 and KG1a, representing blockage at an early stage of
maturation of the erythroid and myeloid lineages [21] showed a
similar metabolic response to the MPA+BEZ treatment whereas
HL-60 cells, which are closer to the mature granulocyte stage [21]
showed a different overall response. HL-60 also showed a less
pronounced combinatorial effect for combined MPA+BEZ
treatment which was clearly distinguished from individual
treatments in KG1a and K562.
Functional annotation of the observed metabolic
changes
Lowered a-ketoglutarate levels associated with increased
succinate concentrations were consistently observed in all three
cell lines when treated with combined BEZ and MPA, and this was
recapitulated by the treatment of KG1a extracts with H2O2
(Figure 6). Thus it is most likely that ROS, generated as a
consequence of drug treatment, are the direct cause of at least
some of the metabolic changes we have observed.
ROS have also been demonstrated to convert pyruvate into
acetate and oxaloacetate into malonate [25] and we have
confirmed these conversions using in vitro tests (Figure S4).
Although we were not able to detect pyruvate in our spectra,
acetate was accumulated in extracts of all three cell lines when
treated with combined BEZ and MPA. Owing to the low transient
concentration of pyruvate acetate was not accumulated in H2O2-
treated control extracts form KG1a cells. Taken together these
observations suggest that flux through the pyruvate pool in HL-60,
K562 and KG1a cells is rapidly maintaining a low steady-state
Figure 1. Phenotypic and metabolic differences among AML cell lines (K562, HL-60 and KG1a). (a) Cell morphology (Jenner-Giemsa
stained cytospins) and fluorescence flow cytometry analysis for apoptosis (Annexin V and propidium iodide double staining) and differentiation
(expression of the erythroid antigen Glycophorin A in K562 and the myeloid differentiation antigen CD11b in HL-60 and KG1a cells; sample results are
compared to an isotype, grey-shaded); typical features of healthy K562, KG1a and HL-60 cells are observed (b)
1H-NMR spectra (expanded between
0.5–4.5 ppm and between 1.95–2.2 ppm in the small insert) collected on AML extracts of HL-60, KG1a and K562 cells (12 replicates per cell line) and
(c) scores plot (PC1 vs PC2) obtained from the PCA of the NMR spectra of 12 datasets per cell line.
doi:10.1371/journal.pone.0004251.g001
Drug Responses in AML Cells
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can the ROS-dependent conversion to a more stable acetate pool
be detected.
Evidence of increased malonate was observed in extracts of HL-
60 cells treated with either BEZ alone or combined BEZ and MPA
but not in the other cell types. Again levels of oxaloacetate were
below detection in all three cell lines. However, the ROS mediated
conversion of oxaloacetate into malonate is confirmed by in vitro
tests. Notably, the drug induced accumulation of malonate by HL-
60 cells was associated with a concomitant fall in fumarate which
again was not observed in either KG1a or K562 cells. Since
malonate is known to inhibit succinate dehydrogenase it is likely
that the malonate and fumarate changes seen exclusively in HL-60
cells are causally linked [24,25]. This may also be linked to
aspartate metabolism as fumarate concentrations were always
inversely correlated to aspartate levels, possibly by an involvement
of the urea cycle as supported by altered ornithine concentrations
in HL-60. In fact, the treatment induced signature of succinate,
malonate, fumarate, and aspartate represents a clear marker
profile of apoptosing KG1a/K562 vs. non-apoptosing HL-60 cells.
The combined impact of dual BEZ and MPA treatment upon
the TCA cycle are likely to impact upon broader aspects of
mitochondrial function. This compromised mitochondrial func-
tionality was also observed in the marked accumulation of
metabolites which are essential for the biosynthesis of nucleotides,
in particular glutamine and glycine, suggesting a hindered
biosynthesis of purine and pyrimidine nucleotides, a known effect
of mitochondrial dysfunction [27,28].
As already highlighted the overall metabolic responses of KG1a
and K562 cells were more similar to each other than to HL-60
cells. This reflects that the drugs primarily induce apoptosis in
KG1a and K562 cells and differentiation in HL-60 cells. In HL-60
cells, purine and pyrimidine have been shown to have an
important role for the progression of cellular differentiation [29–
31]. However, it is not yet possible to determine whether the
differential changes we have observed reflect early commitment to
either apoptosis or differentiation, or indeed in some way ‘instruct’
these pathways. Future studies should address this important
question.
In summary, the data presented in this study highlights the
potential of
1H-NMR based profiling of drug response in cancer
cells. Following other methods of functionally annotated profiling,
the importance of metabolomics is that it describes the actual
functional state of the cells. Metabolic changes observed in AML
cell lines in response to BEZ/MPA treatment reflect the
downstream effect of ROS on TCA cycle metabolites and on
pyruvate and suggest that changes directly induced by ROS
significantly contribute to the mechanism of action.
Materials and Methods
NMR sample preparation
KG1a, K562 and HL-60 AML cell lines were maintained in
exponential proliferation in RPMI 1640 (Gibco-Invitrogen,
Paisley, UK) medium with 10% fetal bovine serum (FBS, Gibco-
Invitrogen) and 100 units/ml Penicillin and 100 mg/ml of
Streptomycin (Gibco-Invitrogen).
5610
7 cells were treated with either solvent control (DMSO),
0.5 mM BEZ, 5 mM MPA or the combination of 0.5 mM BEZ
and 5 mM MPA. Twelve replicate samples were prepared per
treatment. After 24 hours, the cells were washed with PBS (Lonza
Group Ltd., Basel, Swizzerland) and harvested by centrifugation.
The pellets were immediately frozen in liquid nitrogen and stored
at 280uC.
The extraction of intracellular metabolites from cell pellets was
performed using a modified Bligh-Dyer procedure [32]. Samples
were dried overnight in a centrifugal vacuum concentrator. The
dried polar extracts were redissolved in 90% H2O/10% D2O
(GOSS Scientific Instruments Ltd, Essex UK) prepared as
100 mM phosphate buffer (pH 7.0), containing 0.5 mM sodium
3-(trimethylsilyl)propionate-2,2,3,3-d4 (TMSP, Cambridge Isotope
Laboratories) as internal reference.
Figure 2. Effect of treatment with MPA, BEZ and the combination of both agents on AML cell lines (K562, HL60 and KG1a). (a) Cell
morphology and flow cytometry analysis for apoptosis and differentiation are shown in K562, HL-60 and KG1a cells after 24 hrs and 96 hrs of
treatment with the combination of MPA and BEZ. In these AML cell lines, neither apoptosis nor differentiation signatures are observed after a 24 hrs
treatment with MPA and BEZ in combination. Prominent features of apoptosis and differentiation develop after 96 hours of treatment. (b) PCA scores
plot obtained from the analysis of the NMR spectra of all the AML cell lines after 24 hrs of treatment. Solvent control (red), MPA (blue), BEZ (black),
and MPA+BEZ (green) treatments are included, with 12 replicates per treatment per cell line.
doi:10.1371/journal.pone.0004251.g002
Figure 3. Principal component analysis (PCA) scores plots (PC1 vs PC2) including the solvent control (red symbols) and the 3 drug
treatments (MPA: blue, BEZ: black, and MPA+BEZ: green symbols) for K562, HL-60, and KG1a cell lines. The metabolic profile of all the
cell lines is significantly affected by both the individual and the combined treatments with MPA and BEZ.
doi:10.1371/journal.pone.0004251.g003
Drug Responses in AML Cells
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(red line) and MPA+BEZ (green line) for K562, HL-60, and KG1a cells.
doi:10.1371/journal.pone.0004251.g004
Drug Responses in AML Cells
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A 500 MHz Bruker spectrometer equipped with a cryogenically
cooled probe was used for 1D
1Ha n d2 D
1H J-RES [33] NMR data
acquisition. In both cases the water resonance was suppressed using
excitationsculpting[34].1Dspectrawereacquiredusinga90upulse,
and with 5 kHz spectral width, a relaxation delay of 3 s and 128
transients.2D J-RES spectrawerecollectedusing a doublespinecho
sequence with 16 transients per increment and 32 increments.
Strong coupling artifacts were suppressed by phase cycling [35].
Prior to Fourier transformation, 2D J-RES spectra were multiplied
by a combined sine-bell/exponential window function in the direct
dimension and by a sine bell function in the incremented dimension
[36]. Skyline projections were calculated and spectra were aligned.
Selected signals arising from residual solvents, TMSP and BEZ were
Figure 5. Schematic representation of the metabolic pathways showing the most relevant metabolic changes induced by MPA+BEZ
drug treatment for the individual AML cell lines (HL-60 and KG1a). Metabolites in green/red have increased/decreased concentrations upon
combined MPA+BEZ treatment.
doi:10.1371/journal.pone.0004251.g005
Figure 6. Section of
1H-NMR spectra (expanded between 2.3–2.67 ppm) of a de-proteinized extract of untreated KG1a cells (blue
line) and after treatment with 0.2 mM (red line) and 0.8 mM (green line) H2O2.
doi:10.1371/journal.pone.0004251.g006
Drug Responses in AML Cells
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spectra were binned at 0.005 ppm (4 data points). The generalized-
log transformation was applied prior to conducting the multivariate
statistical analysis [37]. NMR data was processed using NMRLab
[38] in the MATLAB (The MathWorks, Inc., Natick, MA)
programming environment. PCA of the projected J-RES NMR
spectroscopy data was carried out using PLS toolbox 4.1 (Version
4.1; Eigenvector Research, Manson, WA). NMR resonances of
metabolites were assigned using the Chenomx NMR Suite (version
5.0; Chenomx Inc., Edmonton, Canada).
Assessment of cell differentiation
Cell differentiation was assessed by measuring differentiation
antigen expression after 24 and 96 hours treatment with combined
MPA and BEZ using flow cytometry (Becton Dickinson FACS
Calibur and Becton Dickinson Cell Quest software) and PE-
CD11b conjugated antibodies for HL-60 and KG1a cells. FITC-
Glycophorin-A was used to determine macrophage differentiation
of K562 (Serotec).
Assessment of Apoptosis by Annexin-V
Apoptosis was evaluated by measuring Annexin-V expression
using the Annexin-V FITC kit (Becton Dickenson, Oxford, UK).
Analyses were carried out by flow cytometry using a Becton
Dickinson FACS Calibur utilising Cell Quest Pro software (Becton
Dickenson, Oxford, UK).
Jenner Giemsa staining of slides
Cytospins were prepared from 75-100 ml of culture. Slides were
air-dried, methanol fixed and stained; First with Jenner staining
solution (VWR) diluted 1/3 in 1 mM sodium phosphate buffer
pH 5.6 (5 min) and second with Giemsa stain (VWR) diluted 1/20
in 1 mM sodium phosphate buffer pH 5.6 (10 min). Slides were
dried and then mounted onto cover-slips using DePex (VWR, UK).
Supporting Information
Figure S1 Loadings plots for the first principal component of the
pairwise comparison for the 3 untreated cell lines. Blue line:
loadings plot of K562 (positive loadings) versus KG1a (negative
loadings); red line: loadings plot of K562 (positive loadings) versus
HL60 (negative loadings). Metabolites showing the most intense
changes are labeled on the plot (Lac, lactate; Ala, alanine; NAA,
N-acetyl-aspartate; Cr, creatine; PCho, phosphocholine; MI, myo-
inositol).
Found at: doi:10.1371/journal.pone.0004251.s001 (0.37 MB EPS)
Figure S2 Scores plots for the pairwise analysis of solvent-
control versus (a) MPA, (b) BEZ, and (c) MPA+BEZ treatment in
the KG1a cell line; (d) section of the loadings plot obtained for the
comparison of the solvent-control versus MPA (blue), BEZ (red),
and MPA+BEZ(green) for KG1a.
Found at: doi:10.1371/journal.pone.0004251.s002 (0.45 MB EPS)
Figure S3 Schematic representation of the metabolic pathways
showing the most relevant metabolic changes induced by
MPA+BEZ drug treatment for K562 AML cell line. Metabolites
colored in green/red have increased/decreased concentrations in
the combined MPA+BEZ treatment.
Found at: doi:10.1371/journal.pone.0004251.s003 (0.34 MB EPS)
Figure S4 In vitro effect of H2O2 treated metabolites. Relative
concentrations obtained from 1D 1H-NMR spectra of a mixture
of oxaloacetate (a), alpha-ketoglutarate (b) and pyruvate (c) (4 mM)
treated with different concentrations of H2O2. Oxaloacetate,
alpha-ketoglutarate and pyruvate are quantitatively converted to
malonate (d), succinate (e) and acetate (f), respectively.
Found at: doi:10.1371/journal.pone.0004251.s004 (0.32 MB EPS)
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